235 related articles for article (PubMed ID: 28248857)
1. Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study.
Chen YY
Medicine (Baltimore); 2017 Mar; 96(9):e5993. PubMed ID: 28248857
[TBL] [Abstract][Full Text] [Related]
2. Association between C-reactive protein gene variant and treatment efficacy of etanercept in ankylosing spondylitis patients receiving hip arthroplasty.
Xu Y; Jiang W; Zhang H
J Clin Lab Anal; 2020 Aug; 34(8):e23343. PubMed ID: 32311164
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms of ABCB1 gene and response to etanercept treatment in patients with ankylosing spondylitis in a Chinese Han population.
Yan RJ; Lou TT; Wu YF; Chen WS
Medicine (Baltimore); 2017 Feb; 96(5):e5929. PubMed ID: 28151874
[TBL] [Abstract][Full Text] [Related]
4. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
Dong Y; Li P; Xu T; Bi L
Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
[TBL] [Abstract][Full Text] [Related]
5. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
7. [Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis].
Wang QH; Zhang SZ; Xue J; Wu HX
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):409-14. PubMed ID: 20731042
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
9. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.
Chou CT; Tsai CY; Liang TH; Chang TM; Lai CH; Wei CC; Chen KH; Lin SC; Yu CL; Liou LB; Luo SF; Lee CS; Hsue YT; Huang CM; Chen JH; Lai NS; Cheng HH; Cheng TT; Lai HM; Tsai WC; Yen JH; Lu LY; Chang CP
Mod Rheumatol; 2010 Dec; 20(6):580-7. PubMed ID: 20683633
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
11. Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis.
Dong X; Zheng Y; Shi TY; Liu HY
Clin Rheumatol; 2015 May; 34(5):915-20. PubMed ID: 25064131
[TBL] [Abstract][Full Text] [Related]
12. Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis.
Xing-Rong W; Sheng-Qian X; Wen L; Shan Q; Fa-Ming P; Jian-Hua X
Medicine (Baltimore); 2018 Aug; 97(31):e11677. PubMed ID: 30075559
[TBL] [Abstract][Full Text] [Related]
13. Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.
He D; Zhu Q; Zhou Q; Qi Q; Sun H; Zachariah LM; Wang G; Reveille JD; Guan Y; Zhou X
Clin Rheumatol; 2017 Aug; 36(8):1819-1826. PubMed ID: 28432524
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.
Wang Y; Yi XD; Lu HL
Med Sci Monit; 2017 Apr; 23():1775-1782. PubMed ID: 28403136
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy Observation for Treating Ankylosing Spondylitis by Chinese Herbs and Recombinant Hu- man Tumor Necrosis Factor Receptor II-Antibody Fusion Protein].
Liu W; Zhang D; Wu YH; Yang HJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):663-7. PubMed ID: 27491222
[TBL] [Abstract][Full Text] [Related]
17. Etanercept in the longterm treatment of patients with ankylosing spondylitis.
Dijkmans B; Emery P; Hakala M; Leirisalo-Repo M; Mola EM; Paolozzi L; Salvarani C; Sanmarti R; Sibilia J; Sieper J; Van Den Bosch F; van der Heijde D; van der Linden S; Wajdula J
J Rheumatol; 2009 Jun; 36(6):1256-64. PubMed ID: 19411393
[TBL] [Abstract][Full Text] [Related]
18. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
[TBL] [Abstract][Full Text] [Related]
19. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study.
Pan JE; Xiong FL; Chen G; Zhang ZW; Xu YJ
Biomed Pharmacother; 2017 Nov; 95():1549-1555. PubMed ID: 28950654
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
